Buscopan (hyoscine butylbromide) waa daawo liddi ku ah antispasmodic oo loo isticmaalo daaweynta xanuunka caloosha iyo casiraadaha ee ka yimaada mindhicirka mindhicirka (IBS), iyo sidoo kale caadooyinka caadada.
Sida ay u shaqeyneyso
Buscopan way ka duwan tahay daawada kale ee daawada antispasmodic ee ah inuusan ka gudbi karin ciribta dhiigga / maskaxda iyo kaliya raadadka ugu yar ee daawada waxay u arkaan inay u socdaan dhiigga.
Halkii, Buscopan waxay u dhaqdaa maxaliga ah muruqyada caloosha si looga hortago dabka. Faa'iidada farqiga u dhaxeeya waa in ay ka fogaato saameynta daaweynta neerfaha sida naaqus ama dawakh.
Waxtarka
Falanqeyn moodo oo la sameeyey si loo qiimeeyo waxtarka leh doorashooyinka daaweynta IBS ayaa qeexay saddex daraasadood oo kiliinik ah oo tilmaamey in Buscopan uu ka fiicnaaday ilbiriqsiyo si loo yareeyo calaamadaha IBS. Daraasado dheeraad ah oo kiliinikada ah ayaa lagu ogaadey in Buscopan uu si fiican u dulqaadan yahay waxyeelada ugu yar. Si kastaba ha ahaatee, daraasaddan oo adeegsanaysa bukaanno ka xanuunsaday "xanuunka caloosha oo adag", laakiin aan loo baahnayn IBS, waxay ogaadeen in acetaminophen uu ahaa mid waxtar u leh Buscopan marka la barbardhigo cirbadda.
Buskopan ayaa hadda dhif ah in lagu qoro Maraykanka laakiin waxaa badanaa lagu dhajin karaa dhakhaatiir ka baxsan Maraykanka
Baaskiilka Buscopan:
- Kiniiniyada Buscopan waa in la qaato oo dhan, ma la calalin.
- U hubso inaad cabto koob buuxa oo biyo ah markaad qaadato Buscopan.
Ilaha:
Ford, et.al. "Saameynta fibreeriyada, daawooyinka laf-dhabarta, iyo saliidda qallalan ee daaweynta cillad maskaxeed xannuunsanaaneed: dib-u-eegis nidaamsan iyo mala-dhaf" BMJ 2008 337: a2313.
Tytgat, G. "Hyoscine butylbromide: dib u eegis adeegsigeeda daaweynta calool-xumada iyo xanuunka." " Drugs 2007 67: 1343-57.
Mueller-Lissner, S. "Daraasada Placebo- iyo Paracetamol-kontoroolka ah ee ku saabsan waxtarka iyo dulqaadashada of oscyline butylbromide ee daaweynta bukaanka qaba xanuunka calool-galka ah ee calool-gala" Pharmacology Alimentary and Therapeutics 2006 23: 1741 - 1748.